miR-451 protects against ischemic stroke by targeting Phd3

Area of Science:

• Biomedical research
• Molecular biology
• Neuroscience

Background:

• Ischemic stroke presents complex challenges in treatment and understanding its pathogenesis.
• MicroRNA-451 (miR-451) was identified as a differentially expressed biomarker in ischemic stroke patients.
• The precise role and therapeutic potential of miR-451 in cerebral ischemia remain to be fully elucidated.

Purpose of the Study:

• To investigate the neuroprotective role of miR-451 in ischemic stroke.
• To identify the molecular targets and mechanisms underlying miR-451's effects in cerebral ischemia.
• To explore the potential of miR-451 as a therapeutic agent for ischemic stroke.

Main Methods:

• Middle cerebral artery occlusion (MCAO) model in mice to simulate ischemic stroke.
• Intracerebroventricular administration of miR-451 mimic and inhibitor to modulate miR-451 levels.
• Validation of Phd3 (also known as Egln3) as a direct target of miR-451.
• Assessment of infarct size, Phd3 expression, p53 levels, and apoptosis (TUNEL staining).

Main Results:

• Administration of miR-451 mimic significantly reduced infarct size in MCAO mice.
• Conversely, miR-451 inhibitor administration led to increased infarct size.
• Phd3 was confirmed as a novel miR-451 target, with its expression inversely correlated to miR-451 levels.
• Reduced Phd3 levels resulted in downregulation of p53, a known target of Phd3, and decreased apoptosis.

Conclusions:

• miR-451 exerts significant neuroprotective effects in cerebral ischemia.
• Phd3 is identified as a novel molecular target of miR-451 in the context of ischemic stroke.
• The protective mechanism involves the miR-451/Phd3/p53 axis, leading to reduced apoptosis and smaller infarct volumes.